Jazz Pharmaceuticals plc
Description
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
About
CEO
Mr. Bruce C. Cozadd
Employees
2,800
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNGS
Address
Waterloo Exchange, Dublin, D04 E5W7, Ireland
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Feb 26, 2025 | 5.83 | — | — | — |
| Nov 7, 2024 | 5.50 | 6.61 | 1.11 | 20.18% |
| Aug 1, 2024 | 4.77 | 5.30 | 0.53 | 11.11% |
| May 2, 2024 | 4.18 | 2.68 | -1.50 | -35.89% |
| Feb 29, 2024 | 5.18 | 5.02 | -0.16 | -3.09% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 9 | — | 17 |
| Average estimate | — | 4.43 | — | 21.88 |
| Low estimate | — | 3.56 | — | 19.61 |
| High estimate | — | 5.17 | — | 24.24 |
| Last year EPS | — | 2.68 | — | 20.21 |
[stock_revenue_estimate]
Growth estimates
Current qtr
15.380%
Next qtr. (Mar 2025)
67.870%
Current year
10.460%
Next year (Dec 2025)
9.410%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 3.83B | 3.66B | 3.09B | 2.36B | 2.16B |
| Cost of revenue | 435.58M | 540.52M | 440.76M | 148.92M | 127.93M |
| Gross profit | 3.40B | 3.12B | 2.65B | 2.21B | 2.03B |
| Operating expense | |||||
| Research & development | 849.66M | 590.45M | 505.75M | 335.38M | 299.73M |
| Selling general and admin | 1.34B | 1.42B | 1.45B | 854.23M | 736.94M |
| Other operating expenses | — | — | — | — | — |
| Operating income | 597.58M | 512.27M | 170.28M | 765.46M | 642.35M |
| Non operating interest income | |||||
| Income | — | — | — | — | — |
| Expense | 289.44M | 288.24M | 278.77M | 99.71M | 72.26M |
| Other income expense | -10.21M | -596.81M | -4.35M | -390.66M | -115.79M |
| Pretax income | 297.93M | -372.78M | -112.84M | 275.10M | 454.30M |
| Tax provision | -119.91M | -158.65M | 216.12M | 33.52M | -73.15M |
| Net income | 414.83M | -224.06M | -329.67M | 238.62M | 523.37M |
| Basic EPS | 6.55 | -3.58 | -5.52 | 4.28 | 9.22 |
| Diluted EPS | 6.10 | -3.58 | -5.52 | 4.22 | 9.09 |
| Basic average shares | 63.29M | 62.54M | 59.69M | 55.71M | 56.75M |
| Diluted average shares | 63.29M | 62.54M | 59.69M | 55.71M | 56.75M |
| EBITDA | 1.24B | 1.14B | 722.76M | 1.04B | 1.01B |
| Net income from continuing op. | 414.83M | -224.06M | -329.67M | 238.62M | 523.37M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 11.39B | 10.84B | 12.30B | 6.54B | 5.54B |
| Current assets | |||||
| Cash | 437.72M | 334.02M | 510.75M | 517.12M | 333.17M |
| Cash equivalents | 1.07B | 547.46M | 80.70M | 540.65M | 304.17M |
| Cash and cash equivalents | 1.51B | 881.48M | 591.45M | 1.06B | 637.34M |
| Other short term investments | 120.00M | — | — | 1.08B | 440.00M |
| Accounts receivable | 705.79M | 651.49M | 563.36M | 396.49M | 355.99M |
| Other receivables | — | — | — | — | — |
| Inventory | 597.04M | 714.06M | 1.07B | 95.40M | 78.61M |
| Prepaid assets | 185.48M | 91.91M | 131.41M | 62.42M | 39.43M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 149.30M | 91.14M | 48.91M | 38.26M | 78.90M |
| Non current assets | |||||
| Properties | 65.34M | 73.33M | 86.59M | 129.17M | 139.39M |
| Land and improvements | 70.91M | 68.94M | 64.01M | 47.56M | 47.05M |
| Machinery furniture equipment | 145.70M | 134.60M | 125.37M | 86.59M | 82.27M |
| Construction in progress | 18.66M | 67.39M | 86.51M | 7.26M | 5.15M |
| Leases | 67.72M | 64.78M | 66.32M | 54.11M | 52.29M |
| Accumulated depreciation | -133.35M | -107.65M | -85.37M | -67.59M | -55.26M |
| Goodwill | 8.92B | 9.18B | 10.81B | 4.11B | 4.28B |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 5.42B | 5.79B | 7.15B | 2.20B | 2.44B |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 551.78M | 440.64M | 363.95M | 285.88M | 276.74M |
| Total liabilities | 7.66B | 7.75B | 8.33B | 2.88B | 2.43B |
| Current liabilities | |||||
| Accounts payable | 102.75M | 90.76M | 100.30M | 26.95M | 45.73M |
| Accrued expenses | 632.14M | 617.91M | 457.44M | 213.68M | 171.93M |
| Short term debt | 624.40M | 46.94M | 46.76M | 260.78M | 46.12M |
| Deferred revenue | — | 463,000 | 2.09M | 2.55M | 4.72M |
| Tax payable | 35.07M | 7.72M | 9.61M | 25.20M | 10.97M |
| Pensions | 121.21M | 143.24M | 158.87M | 102.60M | 80.53M |
| Other current liabilities | 681,000 | — | 18.42M | 3.63M | 1.04M |
| Non current liabilities | |||||
| Long term debt | 5.17B | 5.77B | 6.11B | 1.99B | 1.73B |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | 847.71M | 944.34M | 1.30B | 130.40M | 224.10M |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 104.75M | 106.81M | 117.00M | 101.15M | 109.37M |
| Shareholders equity | |||||
| Common stock | 61,000 | 61,000 | 61,000 | 61,000 | 61,000 |
| Retained earnings | 878.66M | 733.59M | 830.23M | 1.16B | 1.07B |
| Other shareholders equity | -842.15M | -1.13B | -400.36M | -134.35M | -223.39M |
| Total shareholders equity | 3.74B | 3.09B | 3.97B | 3.66B | 3.11B |
| Additional paid in capital | 3.70B | 3.48B | 3.54B | 2.63B | 2.27B |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||
| Net Income | 414.83M | -224.06M | -329.67M | 238.62M | 523.37M | 447.10M | 487.85M | 396.83M | 329.53M | 57.33M | 216.31M | 288.59M | 124.98M | 32.78M | -6.84M | -184.34M | -138.83M | -59.39M | -85.16M |
| Depreciation | 638.70M | 629.47M | 552.48M | 278.25M | 370.16M | 216.73M | 165.15M | 113.78M | 108.06M | 133.68M | 82.09M | 74.23M | 7.83M | 8.71M | 9.10M | 15.03M | 10.53M | 10.31M | 5.44M |
| Deferred Taxes | -260.22M | -292.25M | 69.20M | -136.94M | -236.61M | -88.82M | -225.59M | -41.16M | -68.36M | -49.25M | -10.10M | -113.86M | — | — | — | — | — | — | — |
| Stock-Based Compensation | 226.84M | 222.00M | 189.01M | 121.00M | 110.56M | 102.44M | 106.90M | 98.77M | 91.55M | 69.64M | 44.55M | 23.01M | 20.70M | 8.22M | 5.96M | 8.11M | — | — | — |
| Other Non-Cash Items | 204.17M | 741.03M | 325.77M | 327.58M | 156.43M | 51.32M | 129.35M | 42.14M | 17.55M | 199.94M | 30.29M | 23.16M | 394,000 | 2.41M | 2.81M | 2.06M | 25.56M | -27.02M | 901,000 |
| Accounts Receivable | -51.88M | -90.14M | -92.74M | -38.65M | -92.33M | -40.13M | 12.28M | -25.60M | -24.84M | -55.04M | -48.85M | -4.72M | -12.29M | -9.77M | -5.67M | -1.25M | -250,000 | -1.78M | -249,000 |
| Accounts Payable | 9.60M | -11.23M | 57.02M | -18.94M | 4.77M | 17.04M | 214,000 | 361,000 | -2.28M | -37.97M | 5.09M | -7.29M | 2.08M | 891,000 | -3.58M | 2.88M | — | — | — |
| Other Assets & Liabilities | -37.96M | -88.82M | -55.75M | -22.33M | -45.46M | -14.00M | 31.40M | 5.13M | 27.72M | 5.83M | 937,000 | -7.97M | -3.72M | -6.53M | -24.36M | 12.65M | 30.01M | 17.00M | -468,000 |
| Operating Cash Flow | 1.14B | 886.00M | 715.33M | 748.60M | 790.89M | 691.69M | 707.55M | 590.25M | 478.94M | 324.16M | 320.33M | 275.14M | 139.98M | 36.71M | -22.58M | -144.87M | -72.98M | -60.89M | -79.53M |
| Investing Activities | |||||||||||||||||||
| Capital Expenditures | -23.96M | -29.05M | -27.64M | -15.00M | -40.14M | -20.37M | -28.95M | -9.69M | -35.96M | -36.35M | -9.98M | -5.98M | -1.28M | -731,000 | -53,000 | -1.74M | 7.00M | -1.53M | -1.41M |
| Net Intangibles | -19.00M | -469.15M | -17.89M | -364.25M | -142.20M | -111.10M | -85.00M | -173.75M | — | -202.63M | -6.29M | -16.50M | -4.50M | -4.00M | -6.00M | -21.23M | — | — | — |
| Net Acquisitions | — | 53.00M | -6.23B | 14.26M | — | — | — | -1.50B | 33.70M | -828.68M | — | -448.61M | — | — | — | — | — | — | -146.12M |
| Purchase of Investments | -390.10M | -61.04M | -26.82M | -2.40B | -917.10M | -1.17B | -385.00M | -132.18M | — | — | — | -37.44M | -79.89M | — | -1.08M | -4.44M | -10.85M | -1.71M | — |
| Sale of Investments | 270.00M | 60.00M | 1.10B | 1.76B | 985.00M | 855.00M | 230.00M | 66.91M | — | — | — | 113.23M | 4.03M | — | 1.00M | 3.44M | 10.85M | 1.71M | 5.95M |
| Investing Cash Flow | -144.06M | 22.92M | -5.19B | -629.16M | -13.10M | -283.39M | -183.95M | -1.58B | -2.26M | -865.02M | -9.98M | -378.79M | -76.73M | 1.86M | -1.20M | 9.28M | 5.34M | -1.51M | -153.75M |
| Financing Activities | |||||||||||||||||||
| Long-Term Debt Issuance | — | — | 5.19B | 981.38M | — | — | 559.39M | 994.65M | 898.64M | 1.19B | 553.43M | 450.92M | — | 48.43M | — | 416,000 | — | — | — |
| Long-Term Debt Payments | -31.00M | -582.01M | -1.32B | -889.58M | -33.39M | -25.72M | -886.09M | -178.30M | -1.07B | -309.52M | -465.91M | -11.88M | -49.50M | -138.36M | — | -504,000 | — | — | — |
| Other Financing Charges | -50.95M | -45.44M | -35.60M | -16.88M | -16.74M | -23.08M | -15.44M | -21.23M | -26.18M | -190.10M | -5.59M | -15.51M | — | 3.54M | 5.91M | — | — | 15.00M | 15.00M |
| Financing Cash Flow | -351.71M | -627.51M | 3.84B | -71.61M | -351.58M | -572.47M | -1.29B | 366.81M | -414.85M | 352.55M | -54.56M | 423.53M | -56.85M | -31.62M | 18.22M | 24.84M | 98.48M | 115.00M | 192.85M |
| Other Cash Details | |||||||||||||||||||
| End Cash Position | 1.51B | 881.48M | 591.45M | 1.06B | 637.34M | 309.62M | 386.04M | 365.96M | 988.79M | 684.04M | 636.50M | 387.20M | 82.08M | 44.79M | 15.60M | 24.90M | 102.95M | 78.95M | 20.61M |
| Income Tax Paid | 177.88M | 94.68M | 271.22M | 226.82M | 183.61M | 164.22M | 174.12M | 160.31M | 145.60M | 108.19M | 137.62M | 9.14M | — | — | — | — | — | — | — |
| Interest Paid | 333.11M | 270.67M | 138.27M | 42.47M | 43.00M | 42.71M | 44.61M | 39.90M | 40.10M | 31.98M | 18.28M | 14.19M | 1.62M | 10.23M | 24.49M | 12.80M | — | — | — |
| Free Cash Flow | 1.05B | 773.78M | 732.98M | 520.39M | 594.07M | 667.43M | 579.14M | 408.95M | 495.99M | 168.63M | 272.17M | 227.28M | 145.82M | 54.14M | -21.93M | -158.97M | -84.24M | -59.03M | -53.58M |
Error: Invalid format in Holders JSON file.
Article
Why Jazz (JAZZ) is Poised to Beat Earnings Estimates Again
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Feb 5, 2025
Article
3 Biotech Stocks With Notable Insider Buying
Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-cap biotech and biopharma stocks. Today, we look at three of these names that have seen notable recent purchases from insiders and/or beneficial owners.
Jan 22, 2025
Article
3 Oversold Biotech Names
High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens today and runs through most of the week could boost sentiment on the biotech sector. In the paragraphs below, I highlight three biotech/biopharma names that appear oversold at current trading levels.
Jan 13, 2025
